Who to call at Foghorn Therapeutics Inc., and when
Fundz watches for the moments Foghorn Therapeutics Inc. starts buying, and tells you who to reach.
- An alert the day Foghorn Therapeutics Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Foghorn Therapeutics Inc., from your own LinkedIn network
Foghorn Therapeutics Inc.
The company announced a restructuring, such as layoffs or closing a site. An 8-K is the notice a US public company must file within four business days of a major event.
foghorntx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Foghorn Therapeutics and Eli Lilly terminated their collaboration on the Phase 1 trial of FHD-909, deciding not to advance into the expansion phase based on clinical data assessment. The company is reallocating resources to other portfolio programs with greater potential to address patient needs and create shareholder value.
Key Takeaways
FHD-909 Phase 1 trial collaboration with Eli Lilly has been terminated effective September 25, 2026
Clinical data assessment led to the decision not to advance the trial into the expansion phase
2 more takeaways
Related Filings (1)
1 more filing from Foghorn Therapeutics Inc. in the last 90 days
Filing Overview
What This Means
Foghorn Therapeutics Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.